Quick Answer
A calm, evidence-based explanation of MGUS, progression risk and monitoring.
Medically reviewed by Dr. Sachita Baniya • NMC 20158 • Kathmandu Neurology Clinic & Cognitive Center
MGUS — monoclonal gammopathy of undetermined significance — is a common finding on blood or urine protein testing. It means a small clone of plasma cells is producing a monoclonal protein, but there is no organ damage and no evidence of myeloma.
How MGUS is defined
- Serum M-protein below 30 g/L
- Bone marrow plasma cells below 10%
- No myeloma-defining events
- No anaemia, kidney failure, high calcium or bone lesions attributable to the clone
Does MGUS become myeloma?
Most people with MGUS never develop myeloma. The annual risk of progression is low but persists for decades, so monitoring is recommended. Risk is higher with a larger M-protein, an abnormal free light chain ratio and a non-IgG isotype.
What monitoring involves
Monitoring usually includes blood counts, serum protein electrophoresis, free light chains and clinical review. The interval depends on risk and stability. New bone pain, anaemia, kidney problems or high calcium should prompt earlier assessment.
What MGUS does not require
MGUS does not require chemotherapy. It does not usually require a bone marrow test unless the M-protein is high, the free light chain ratio is abnormal or progression is suspected. Treatment is reserved for progression to symptomatic myeloma or a related disorder.
Can MGUS cause symptoms?
MGUS itself usually causes no symptoms. A minority of patients develop peripheral neuropathy or other complications related to the monoclonal protein. These need specialist evaluation.
The bottom line
MGUS is a monitoring diagnosis, not a cancer diagnosis. Regular follow-up and prompt review of new symptoms are the most important steps. Most patients live normal lives without ever needing treatment.
Frequently asked questions
Answers reviewed by Dr. Jitendra Prasad Yadav • MBBS, MD (Internal Medicine), FICN (Neurology), FCNV, FIHM • NMC 8029
No. Most people with MGUS never develop myeloma. The annual progression risk is low but persists, so monitoring is recommended.
Monitoring is usually every few months initially and then less often for stable low-risk disease. The schedule is individualised.
Active myeloma has organ damage or myeloma-defining events. Smouldering myeloma has laboratory abnormalities but no such events and is usually observed.
Monitoring is usually more frequent than for MGUS, often every few months, and depends on risk and stability.
More: All FAQs → · Ask Dr. Jitendra →
Related articles
Multiple Myeloma: A Practical Guide for Patients and Families
Myeloma is a treatable plasma cell cancer. Understand the tests, treatment options, transplant and supportive care.
Blood Cancer Symptoms: When to See a Haematologist
Unexplained bruising, persistent fatigue, swollen lymph nodes or repeated infections can be early signs of a blood disorder. Here is when to seek a haematology opinion.
Bone Marrow Transplant: Autologous, Allogeneic and Haplo-Identical
What a bone marrow transplant involves, who it is for, and the difference between autologous, allogeneic and haplo-identical approaches.
Medical Disclaimer
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
References & Review
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
- International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Harrison's Principles of Internal Medicine — Neurology sections.
- American Academy of Neurology guidelines for selected conditions (where applicable).
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.